It will be two to three years before Novo Nordisk will be able to present data from a cardiovascular safety study for its insulin degludec Tresiba in people with diabetes (PMLiVE)
Diabetes News Service
Glycosmedia is also available as an App:
For iPhone and iPad | For Android devices
Sponsorship and Advertising
For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com
